ATAI Life Sciences
A biotechnology company pioneering mental health innovation.
Launch date
Employees
Market cap
$218m
Enterprise valuation
$149m (Public information from Sep 2024)
Share price
$1.26 ATAI
Company register number HRB 239201 (München)
Berlin Germany (HQ)
Financials
Estimates*
| EUR | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | 18.5m | <1m | <1m | <1m | <1m |
| % growth | - | - | - | (99 %) | 35 % | (46 %) | 76 % |
| EBITDA | 1.4m | (89.5m) | (95.3m) | (131m) | (110m) | - | - |
| % EBITDA margin | - | - | (515 %) | (61834 %) | (38551 %) | - | - |
| Profit | (12.9m) | (154m) | (153m) | (139m) | (36.6m) | - | - |
| % profit margin | - | - | (824 %) | (65401 %) | (12810 %) | - | - |
| R&D budget | 2.8m | 10.4m | 43.6m | 67.6m | 56.5m | - | - |
| R&D % of revenue | - | - | 235 % | 31894 % | 19810 % | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | $3.6m | Seed | |
$25.0m | Series A | ||
$43.0m | Series B | ||
| N/A | N/A | Secondary | |
* | $24.0m | Convertible | |
| N/A | $8.0m | Convertible | |
$125m | Series C | ||
$157m Valuation: $2.0b -20.3x EV/LTM EBITDA | Series D | ||
| N/A | $225m Valuation: $2.3b -23.4x EV/LTM EBITDA | IPO | |
* | $175m | Post IPO Debt | |
| Total Funding | $386m | ||
Related Content
Recent News about ATAI Life Sciences
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by ATAI Life Sciences
Edit
exited
ACQUISITION by ATAI Life Sciences Apr 2021
ACQUISITION by ATAI Life Sciences Jan 2021